Literature DB >> 1419642

Competing risks determining event-free survival in early breast cancer.

R Arriagada1, L E Rutqvist, A Kramar, H Johansson.   

Abstract

To evaluate the natural history of a disease and the effects of therapeutic interventions, it is important to determine which are the causes of treatment failure and to assess the extent to which each cause contributes to the total failure rate. The paper presents a new biostatistical technique to decompose the total event-free survival of a diseased population into cause-specific failure rates. The technique was based on a competing risk approach thereby avoiding biases related to assumptions of independence between different types of event. Such assumptions are inherent in the conventional Kaplan-Meier or actuarial methods. The competing risk method was used to analyse the pattern of failure among 2,850 pre- and postmenopausal patients with early-stage breast cancer and the results were compared to those obtained using conventional methods. The following events were analysed: loco-regional recurrence, distant metastasis, contralateral breast cancer, other new primary malignancies, and intercurrent deaths. The rate of new primary malignancies was found to be significantly higher in post- than in premenopausal patients (6% vs 3% at 10 years). In low-risk, node-negative postmenopausal patients the incidence of recurrences from breast cancer were found to be no greater than other types of events. This observation highlights the significance of the effect of different adjuvant therapies not only on the disease itself but also on the risk of second primary malignancies and other intercurrent diseases. In general, it was found that the conventional statistical methods tended to overestimate the event-specific rates. In conclusion, the method based on competing risks permits an unbiased analysis of all types of events determining the total event-free survival. It is thus useful for the description of the natural history of breast cancer as well as other diseases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419642      PMCID: PMC1977968          DOI: 10.1038/bjc.1992.391

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  A rapid, sensitive and specific radioimmunoassay for human chorionic gonadotrophin.

Authors:  A Kardana; K D Bagshawe
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

2.  The histopathology of trophoblastic tumours.

Authors:  C W Elston
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1976

3.  Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group.

Authors:  M Castiglione; R D Gelber; A Goldhirsch
Journal:  J Clin Oncol       Date:  1990-03       Impact factor: 44.544

4.  Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies.

Authors:  R Arriagada; L E Rutqvist
Journal:  Lancet       Date:  1991-08-31       Impact factor: 79.321

5.  Ultrasonic morphology of the uterus and ovaries after treatment of invasive mole and gestational choriocarcinoma.

Authors:  M G Long; J E Boultbee; R H Begent; K D Bagshawe
Journal:  Br J Radiol       Date:  1990-12       Impact factor: 3.039

6.  Preliminary Doppler studies on the uterine artery and myometrium in trophoblastic tumours requiring chemotherapy.

Authors:  M G Long; J E Boultbee; R H Begent; M E Hanson; K D Bagshawe
Journal:  Br J Obstet Gynaecol       Date:  1990-08

7.  Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Authors:  G Bonadonna; E Brusamolino; P Valagussa; A Rossi; L Brugnatelli; C Brambilla; M De Lena; G Tancini; E Bajetta; R Musumeci; U Veronesi
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

8.  Improved methodology for analyzing local and distant recurrence.

Authors:  R Gelman; R Gelber; I C Henderson; C N Coleman; J R Harris
Journal:  J Clin Oncol       Date:  1990-03       Impact factor: 44.544

9.  Placental site trophoblastic tumour (trophoblastic pseudotumour): a study of four cases requiring hysterectomy including one fatal case.

Authors:  R P Eckstein; F J Paradinas; K D Bagshawe
Journal:  Histopathology       Date:  1982-03       Impact factor: 5.087

10.  Competing events determining relapse-free survival in limited small-cell lung carcinoma. The French Cancer Centers' Lung Group.

Authors:  R Arriagada; A Kramar; T Le Chevalier; H De Cremoux
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

View more
  5 in total

1.  Prognostic factors and natural history in lymph node-negative breast cancer patients.

Authors:  R Arriagada; L E Rutqvist; L Skoog; H Johansson; A Kramar
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer.

Authors:  R A Nout; W E Fiets; H Struikmans; F R Rosendaal; H Putter; J W R Nortier
Journal:  Breast Cancer Res Treat       Date:  2007-07-28       Impact factor: 4.872

3.  Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients.

Authors:  D Azria; S Gourgou; W J Sozzi; A Zouhair; R O Mirimanoff; A Kramar; C Lemanski; J B Dubois; G Romieu; A Pelegrin; M Ozsahin
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

4.  Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial.

Authors:  David Azria; Olivier Riou; Florence Castan; Tan Dat Nguyen; Karine Peignaux; Claire Lemanski; Jean-Léon Lagrange; Youlia Kirova; Eric Lartigau; Yazid Belkacemi; Céline Bourgier; Sofia Rivera; Georges Noël; Sébastien Clippe; Françoise Mornex; Christophe Hennequin; Andrew Kramar; Sophie Gourgou; André Pèlegrin; Pascal Fenoglietto; Esat Mahmut Ozsahin
Journal:  EBioMedicine       Date:  2015-10-25       Impact factor: 8.143

5.  Long-Term Disease-Free Survival of Non-Metastatic Breast Cancer Patients in Iran: A Survival Model with Competing Risks Taking Cure Fraction and Frailty into Account

Authors:  Vahid Ghavami; Mahmood Mahmoudi; Abbas Rahimi Foroushani; Hossein Baghishani; Fatemeh Homaei Shandiz; Mehdi Yaseri
Journal:  Asian Pac J Cancer Prev       Date:  2017-10-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.